Literature DB >> 2159697

Fibrolamellar hepatoma.

M T Ruffin1.   

Abstract

Primary hepatocellular carcinoma (HCC) has a high incidence rate worldwide with an extremely grave prognosis, but, fortunately, accounts for only 2% of all cancers in the United States. Yet, a unique subset of HCC fibrolamellar hepatocellular carcinoma (FLHC) is reported only from the United States. Five cases of FLHC from the University of Minnesota's 17 years of experience are reported and compared with the literature reports for FLHC, as well as contrasted to reports of HCC. The review of the literature is addressed for data evaluating FLHC as a distinct entity from HCC.

Entities:  

Mesh:

Year:  1990        PMID: 2159697

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

2.  Mediastinal metastasis from a fibrolamellar hepatocellular carcinoma: Report of a case.

Authors:  Yoshinobu Ichiki; Kenji Sugio; Tetsuro Baba; Makiko Mizukami; Takeshi Oga; Mitsuhiro Takenoyama; Takeshi Hanagiri; Koji Okamoto; Koji Yamaguchi; Satoshi Katagiri; Masakazu Yamamoto; Kosei Yasumoto
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

Review 3.  Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature.

Authors:  S Saab; F Yao
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  Fibrolamellar hepatocellular carcinoma in mexican patients.

Authors:  Julian Arista-Nasr; Lisa Gutierrez-Villalobos; Juan Nuncio; Hector Maldonaldo; Leticia Bornstein-Quevedo
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

5.  Late supra-diaphragmatic lymph node recurrence following resection of a fibrolamellar hepatocarcinoma: an unusual case.

Authors:  Basile Tsilividis; Emmanuel Huet; Jean Lubrano; Laurence Lacaze; Jean Pierre Lestrat; Arnaud François; Ghassan Riachi; Michel Scotté
Journal:  Surg Radiol Anat       Date:  2009-09-24       Impact factor: 1.246

6.  Typical fibrolamellar hepatocellular carcinoma in Japanese patients: report of two cases.

Authors:  J Tanaka; N Baba; S Arii; K Fujita; J Tamura; Y Kawakami; S Tsuji; M Imamura; H Yamabe; S Nakai
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma.

Authors:  Laura E Moreno-Luna; Oscar Arrieta; Jorge García-Leiva; Braulio Martínez; Aldo Torre; Misael Uribe; Eucario León-Rodríguez
Journal:  BMC Cancer       Date:  2005-10-31       Impact factor: 4.430

8.  Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period).

Authors:  Mohamed Abdel Wahab; Ehab El Hanafy; Ayman El Nakeeb; Mahmoud Abdelwahab Ali
Journal:  World J Gastrointest Surg       Date:  2017-02-27

9.  Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Authors:  Ahmed Omar Kaseb; Manal Hassan; Sahin Lacin; Reham Abdel-Wahab; Hesham M Amin; Ahmed Shalaby; Robert A Wolff; James Yao; Asif Rashid; Bharathi Vennapusa; Janine Feng; Toshihiko Ohtomo
Journal:  Oncotarget       Date:  2016-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.